Americans have struggled to make it through a tough year and will the holidays approaching the global coronavirus pandemic could cancel plans to celebrate but there is good news from companies working on a successful vaccine.
Pfizer and Moderna have both announced that their coronavirus vaccines have had incredible results during clinical trials and there could be as many as 40 million doses available by the end of the year.
Now, there’s a new contender in the ring and their numbers seem to indicate that the third time’s a charm.
Pharmaceutical company AstraZeneca said Monday that late-stage trials showed its coronavirus vaccine was up to 90% effective, giving public health officials hope they may soon have access to a vaccine that is cheaper and easier to distribute than some of its rivals.
The results are based on interim analysis of trials in the U.K. and Brazil of a vaccine developed by Oxford University and manufactured by AstraZeneca. No hospitalizations or severe cases of COVID-19 were reported in those receiving the vaccine.
AstraZeneca is the third major drug company to report late-stage results for a potential COVID-19 vaccine as the world anxiously waits for scientific breakthroughs that will bring an end to a pandemic that has wrought economic devastation and resulted in nearly 1.4 million confirmed deaths.
The key factor here is the ease of distribution, as a large part of the population will need to be vaccinated immediately before the world can make the transition back to normalcy.
The only problem we have now is to convince the world’s most hardcore anti-vaxxers to trust science.